SecBot SecBot
Insider Cluster (2 insiders) ·Filed Sep 14, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed2mo ago
Insider cluster: 2 insiders, $427K total
Actionable Insight • Neutral

The insider sales are too small in dollar terms and relative to market cap to warrant a bearish read. Monitor for any larger insider sales or a change in the pattern, but this cluster alone does not suggest material negative information.

DirectionNeutral
Confidencemedium
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$276.98
T+0 close · Sep 14, 2026 · via day close
Latest settled
+9.59%
T+20 · $303.53 · next T+60 in 22d
Vs SPY
+6.86%
α at T+20
Latest observation
+20.29%
T+42 · FF3 residual α
  1. T+0 · Sep 15 $276.98entry
  2. T+1 · 2mo ago −0.64%α −0.20% · $275.20
  3. T+5 · 8w ago +7.77%α +5.66% · $298.50
  4. T+20 · 5w ago +9.59%α +6.86% · $303.53
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Ligand Pharmaceuticals sold a combined $427K in open-market transactions over a one-week window. The sales are small relative to the $5.7B market cap (0.007%), and the cluster consists of a CLO and a director, not the CEO or CFO, limiting the informational signal.

Key Financial Metrics

Direction
selling
Total Value
$427.0K
Insiders
2

Key Facts

  • Two insiders sold shares between Sept 3 and Sept 10, 2026
  • Total sale value: $427K (0.007% of $5.7B market cap)
  • Sellers: CLO Andrew Reardon ($85K) and Director Martine Zimmermann ($342K)
  • No CEO or CFO sales in the cluster
  • 94% of analysts rate the stock as Buy or Strong Buy

Financial Impact

Total insider sales of $427K represent a negligible 0.007% of market cap

insider_ownership

Risk Factors

  • Insider sales could accelerate if management becomes less confident
  • The stock has high institutional ownership (BlackRock, Invesco, Vanguard), any large fund trim could pressure shares

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1789419701379

US Market Status

Market Closed · Opens Wed (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026